News

Cathy Tie slips on a white lab coat bearing her name and the logo of her startup: Origin Genomics. "Welcome!" she says as she leads an NPR reporter, photographer and videographer on an exclusive tour of Origin's labs located...

This is the 17th installment in the Legacies of Eugenics series, which features essays by leading thinkers devoted to exploring the history of eugenics and the ways it shapes our present. The series is organized by Osagie K. Obasogie in...

THE INSTAGRAM POST, precision-guided by sex and age, had zeroed in on its target. Yuchen Tu is a conser­vatory-trained viola...

This is the 16th installment in the Legacies of Eugenics series, which features essays by leading thinkers devoted to exploring...

By Marcy Darnovsky, Genetic Crossroads | 02.28.2007

The UK-based Human Genetics Alert (HGA) has launched a campaign to prevent Britain from becoming the first country in the...

By Nicholas Bakalar , New York Times | 02.27.2007

Black women have significantly higher rates of premature birth than white women, and a new study suggests there may be...

By Jennifer Viegas, Discovery News | 02.25.2007

New scientific evidence, including DNA analysis conducted at one of the world's foremost molecular genetics laboratories, as well as studies...

By This is London, thisislondon.co.uk | 02.24.2007

Scientists will be able to carry out genetic experiments on human embryos for the first time under controversial Government plans...

Press Statement

Center for Genetics and Society says California agency must provide for affordable treatments and returns to the state

The Center for Genetics and Society, a public interest group, today welcomed the introduction of a bipartisan bill to the California Legislature to ensure that the state receives a share of profits, as well as discounted prices to any treatments, from publicly funded stem cell research.

“If a biotech company is making billions of dollars of profit from state-financed research, the people should receive a fair return on their investment, as well as access to any therapies,” said Jesse Reynolds, a policy analyst at the Center.

Senate Bill 771, introduced yesterday by Senators Sheila Kuehl (D-Santa Monica) and George Runner (R-Antelope Valley), specifies that minimum percentages of revenue from the licensing of products developed with grants from the California Institute for Regenerative Medicine (CIRM) be returned to the state. It also requires that such products be offered at discounted prices to the state’s publicly funded health care programs.

"The stem cell institute has said it looks forward to working with the Legislature, but in the past its leadership has been combative,” Reynolds said. “Let’s hope they have a new attitude.”

Deborah Ortiz, a former Senator and a vocal proponent of Proposition 71, introduced similar bills in recent legislative sessions, but the CIRM leadership strongly fought these efforts.

“The Proposition 71 campaign sponsored and advertised an economic report claiming the state would receive up to a billion dollars from sharing revenue,” Reynolds continued. “But after it was approved, the leadership of the stem cell institute that it established tried to back out. This would have been a billion-dollar bait and switch. The bill will make significant steps toward fulfilling these promises.”

The study claimed that if the state received a 2% to 4% share of revenues, it would garner $537 million and $1.1 billion. In a recent critique, the former chair of the UC Berkeley Department of Economic, Richard Gilbert, estimated a range twenty times lower.

The Center for Genetics and Society is a public interest organization advocating responsible use and effective societal governance of the new human biotechnologies. It supports human embryonic stem cell research and public funding for it, but has raised concerns about the conduct, oversight, and implications of stem cell research. CGS has been a prominent critic of the $3-billion California stem cell research program.  For more information, see our website at www.genetics-and-society.org and our blog, Biopolitical Times, at www.biopoliticaltimes.org.


Contact:
Jesse Reynolds
510-625-0819 x308


 

By Dr. Allan Kornberg, Business Week | 02.21.2007

Ten years after scientists produced the first clone of a mammal, a sheep named Dolly, the U.S. Food and Drug...

By Martha Irvine, Washington Post | 02.19.2007

CHICAGO -- Human egg donation was a rarity not so long ago. But heightened demand for eggs -- and rising...

By Gina Kolata, New York Times | 02.18.2007

IN the old days, nearly two decades ago, when Jeffrey Harrison was selling his sperm to California Cryobank, sperm banks...